- Home
- FSUN vs AUPH Comparison
FSUN vs AUPH Comparison
Compare FSUN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSUN
- AUPH
- Stock Information
- Founded
- FSUN 1892
- AUPH 1993
- Country
- FSUN United States
- AUPH Canada
- Employees
- FSUN N/A
- AUPH N/A
- Industry
- FSUN Major Banks
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- FSUN Finance
- AUPH Health Care
- Exchange
- FSUN Nasdaq
- AUPH Nasdaq
- Market Cap
- FSUN 997.3M
- AUPH 1.1B
- IPO Year
- FSUN N/A
- AUPH 1999
- Fundamental
- Price
- FSUN $37.51
- AUPH $8.86
- Analyst Decision
- FSUN Buy
- AUPH Strong Buy
- Analyst Count
- FSUN 4
- AUPH 2
- Target Price
- FSUN $47.33
- AUPH $11.50
- AVG Volume (30 Days)
- FSUN 205.1K
- AUPH 1.9M
- Earning Date
- FSUN 08-27-2025
- AUPH 07-31-2025
- Dividend Yield
- FSUN N/A
- AUPH N/A
- EPS Growth
- FSUN N/A
- AUPH N/A
- EPS
- FSUN 3.07
- AUPH 0.27
- Revenue
- FSUN $374,445,000.00
- AUPH $247,295,000.00
- Revenue This Year
- FSUN $18.18
- AUPH $12.15
- Revenue Next Year
- FSUN $6.75
- AUPH $18.31
- P/E Ratio
- FSUN $12.25
- AUPH $33.04
- Revenue Growth
- FSUN 9.58
- AUPH 29.20
- 52 Week Low
- FSUN $31.70
- AUPH $5.20
- 52 Week High
- FSUN $45.32
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- FSUN 63.90
- AUPH 64.10
- Support Level
- FSUN $36.48
- AUPH $7.36
- Resistance Level
- FSUN $38.87
- AUPH $9.10
- Average True Range (ATR)
- FSUN 1.12
- AUPH 0.44
- MACD
- FSUN 0.36
- AUPH 0.10
- Stochastic Oscillator
- FSUN 78.60
- AUPH 89.53
About FSUN FirstSun Capital Bancorp
Firstsun Capital Bancorp is the financial holding company. It provides a full range of deposit, lending, treasury management, wealth management, and online banking products and services. The company operates in two segments - Banking operations and mortgage operations, the majority of which are generated by the banking operations segment. The Banking segment originates loans and provides deposits and fee based services to consumer, business, and mortgage lending customers. Products offered include a full range of commercial and consumer banking and financial services. The Mortgage Operations segment originates, sells, services, and manages market risk from changes in interest rates on one-to-four family residential mortgage loans.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.